# Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis

> **NCT01856803** · PHASE4 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 300 (actual)

## Conditions studied

- Leukemia, GVHD, ATG, Transplantation

## Interventions

- **DRUG:** anti thymoglobulin

## Key facts

- **NCT ID:** NCT01856803
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2018-06
- **Final completion:** 2019-06
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01856803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01856803, "Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01856803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*